Atezolizumab (Tecentriq) is a cancer immunotherapy drug that works by blocking a protein called programmed death-ligand 1 (PD-L1). PD-L1 is a protein that helps cancer cells evade the immune system. By blocking PD-L1, atezolizumab helps the immune system recognize and attack cancer cells.
Atezolizumab is approved by the U.S. Food and Drug Administration (FDA) to treat a variety of cancers, including:
- Non-small cell lung cancer (NSCLC)
- Metastatic triple-negative breast cancer
- Advanced bladder cancer
- Head and neck cancer
- Merkel cell carcinoma
- Hodgkin lymphoma
- MSI-high solid tumors
Atezolizumab is given as an infusion (drip) into a vein. The recommended dose and schedule vary depending on the type of cancer being treated.
Atezolizumab is generally well-tolerated, but it can cause some side effects, such as:
- Fatigue
- Infusion reactions
- Rash
- Diarrhea
- Nausea and vomiting
- Pneumonitis (inflammation of the lungs)
- Hepatotoxicity (liver damage)
- Hypothyroidism (low thyroid hormone levels)
Serious side effects of atezolizumab can also occur, such as:
- Immune-related adverse events (IRAEs), which can affect any part of the body
- Death
If you are considering atezolizumab treatment, it is important to weigh the benefits and risks with your doctor.
Here are some additional things to keep in mind about atezolizumab:
- It is not a cure for cancer.
- It can cause side effects, some of which can be serious.
- It is important to monitor your health closely while taking atezolizumab.
- If you experience any side effects, tell your doctor right away.
Comments
Post a Comment